The medical devices market in Russia reached a revenue of nearly 741 billion Russian rubles in 2020, having more than doubled from the previous year. In 2021, the market size was expected to decrease slightly before increasing to around 762.6 billion Russian rubles in 2022.

Medical devices for diagnostic visualization occupied the largest share of the medical devices market in Russia in 2021, at one fifth of the total revenue. Technology for laboratory (in-vitro) diagnostics accounted for a slightly lower share.

The medical consumables market in Russia showcased a notable trajectory of growth which is related to several key factors shaping the healthcare landscape in the country.

Over the last two observations, the revenue is forecast to significantly increase in all segments. As part of the positive trend, the revenue reaches the maximum value for all six different segments at the end of the comparison period. Particularly noteworthy is the segment Other Medical Devices, which has the highest value of 1.3 billion U.S. dollars. Find other insights concerning similar markets and segments, such as a comparison in Hungary regarding revenue. The Statista Market Insights cover a broad range of additional markets.

Comprehensive dataset of 2 Medical equipment manufacturers in Tver Oblast, Russia as of June, 2025. Includes verified contact information (email, phone), geocoded addresses, customer ratings, reviews, business categories, and operational details. Perfect for market research, lead generation, competitive analysis, and business intelligence. Download a complimentary sample to evaluate data quality and completeness.

As the population expands and healthcare spending grows, medical and dental instruments and supplies manufacturers in Europe enjoy good demand. An ageing population across European nations and rising chronic disease cases fuel demand for healthcare services. However, manufacturers also face challenges, including strict regulatory burdens and intense competition. Revenue is expected to contract at a compound annual rate of 2.9% to €127.7 billion over the five years through 2024, including a drop of 0.3% in 2024. The profit margin is estimated at 16.7%.

Favourable demographics support demand for medical and dental instruments. Strong healthcare sectors and significant funding across European nations benefit medical and dental equipment manufacturers. However, local manufacturers have to contend with competition from cheaper import alternatives, particularly from Asian countries, putting pressure on prices. Despite this, Europe’s renowned reputation for high-quality, advanced medical equipment supports exports. Stricter EU regulations, like the MDR and IVDR, have severely inflated compliance costs for manufacturers. While the COVID-19 pandemic boosted health spending and demand for certain products, it negatively affected non-essential services like regular check-ups. Supply chain issues, heightened manufacturing costs and the Russia-Ukraine conflict have posed challenges to European manufacturers since 2022, hampering production and weakening revenue.

Revenue is forecast to expand at a compound annual rate of 5.5% to €167.2 billion over the five years through 2029. The ageing European population will create a steady demand for healthcare services - a big win for medical and dental equipment manufacturers. Technological advances, like 3D printing, will make it faster and cheaper to produce equipment while improving patient care. However, major hurdles for manufacturers include the strict regulations and upcoming bans on certain chemicals in Europe alongside increasing competition from Asia. Efficiency gains through automation and digital processes, along with strong demand for healthcare services, will support manufacturers’ profitability.

The number of users in the 'Digital Fitness & Well-Being' segment of the digital health market in Russia was forecast to continuously increase between 2024 and 2029 by in total 12.9 million users (+34.74 percent). After the tenth consecutive increasing year, the indicator is estimated to reach 50.03 million users and therefore a new peak in 2029. Notably, the number of users of the 'Digital Fitness & Well-Being' segment of the digital health market was continuously increasing over the past years.Find more key insights for the number of users in countries and regions like the number of users in the 'Fitness Trackers' segment of the digital health market in the United Kingdom and the number of users in the 'Smartwatches' segment of the digital health market in the world. The Statista Market Insights cover a broad range of additional markets.

The demographic trend of an ageing European population is reshaping the retail market for medical supplies, notably due to the increased prevalence of issues like reduced mobility and hearing impairment among seniors. This shift bolsters the sales of medical and orthopaedic supplies across the continent, particularly as seniors become a more significant consumer segment for these products. Traditional pharmacy chains are diversifying into the medical devices sector, offering items like blood pressure monitors at competitive prices and challenging specialised retailers. Online retailers compound the competition with lower-priced offerings attributable to their minimal operational expenses. Major companies are strategically acquiring smaller businesses to enhance their global reach and strengthen their European market standing. These trends underline a robust market environment catering to the senior demographic's needs, with expanding product ranges, competitive pricing and industry consolidation contributing to overall profitability and dynamism within the sector. However, online retailers are capturing a larger market share by offering basic medical supplies at competitive prices and providing a more convenient shopping experience. This shift is leading to a decline in revenue within the traditional medical supply industry. Industry revenue is forecast to decline at a compound annual rate of 5.4% over the five years through 2024 to €373.7 billion, including estimated drop of 3.5% in 2024, while the average industry profit margin is expected to reach 9.5%. A hike in the hearing aid market is likely because of rising healthcare standards. In response, industry trends suggest medical orthopaedic retailers will diversify their offerings and add services like hearing tests to enhance market presence. Retailers are capitalising on the opportunity to facilitate increased hearing aid sales through the provision of comprehensive services, meeting the evolving demands of an ageing population in pursuit of hearing health solutions. Industry revenue is forecast to grow at a compound annual rate of 1.1% over the five years through 2029 to €395.3 billion.

Driven by healthier demand for high-tech medical devices for diagnostic and treatment purposes, the Electromedical and Imaging Equipment Manufacturing industry has seen reasonably strong demand in recent years. Revenue is anticipated to grow at a compound annual rate of 3.1% over the five years through 2025 to €56 billion, including estimated growth of 0.5% in 2025. The industry continues to benefit from the ageing of the European population, with more individuals requiring medical attention and advanced healthcare services. Furthermore, poor lifestyle choices, like a lack of exercise and poor eating habits, are leading to issues like obesity, inflating demand for medical services. As diseases related to these issues become more difficult to detect, manufacturers are pouring more money into developing increasingly sophisticated machinery. These products can command premium pricing, driving revenue growth. Manufacturers rely heavily on foreign trade, exposing them to fluctuating exchange rates. In response to a volatile euro, manufacturers use financial instruments like forward contracts or options to hedge against exchange rate risks, locking in favourable rates to help stabilise earnings. There have been notable advancements in technology in recent years, like wireless connectivity in hearing aids and improvements in pacemaker functionality. Countries like the Netherlands have positioned themselves as centres for medical equipment manufacturing, benefitting from government-backed investments in R&D. The industry is poised for future growth. Revenue is slated to swell at a compound annual rate of 4.3% in the five years through 2030 to €69 billion. Demographic trends, most notably the continued ageing of the European population, will drive demand for diagnostic medical devices and hearing aids. Technological advancements like AI are set to enhance medical equipment, propelling demand. Climbing demand for security scanning equipment, fuelled by innovations in airport scanners, will also drive up sales. Geopolitical tensions will incite onshoring activity as manufacturers look to limit their dependency on non-EU supply chains and make their own supply networks more resilient. This will stabilise revenue in times of uncertainty and protect profitability.

This dataset provides information on 12,088 in Russia as of June, 2025. It includes details such as email addresses (where publicly available), phone numbers (where publicly available), and geocoded addresses. Explore market trends, identify potential business partners, and gain valuable insights into the industry. Download a complimentary sample of 10 records to see what's included.

Comprehensive dataset of 1 Medical equipment manufacturers in Saint Petersburg, Russia as of June, 2025. Includes verified contact information (email, phone), geocoded addresses, customer ratings, reviews, business categories, and operational details. Perfect for market research, lead generation, competitive analysis, and business intelligence. Download a complimentary sample to evaluate data quality and completeness.

The Russian diabetes care devices market, while lacking precise figures in the provided data, presents a compelling opportunity for growth. Considering the global market size of $1.34 billion in 2025 with a 4.53% CAGR, and the global prevalence of diabetes, we can infer a significant, albeit currently unspecified, market presence in Russia. Russia's aging population and increasing rates of type 2 diabetes, driven by lifestyle factors such as poor diet and reduced physical activity, are key market drivers. Furthermore, rising healthcare expenditure and government initiatives aimed at improving diabetes management contribute to positive market dynamics. However, economic factors and the potential for limited healthcare access in certain regions could act as restraints. The market is segmented by device type (self-monitoring blood glucose devices, continuous glucose monitoring devices, and insulin delivery devices) and distribution channels (online and offline). Major players like Abbott Diabetes Care, Roche, and Medtronic, already established globally, likely hold significant market share in Russia, competing with local and regional distributors. Growth is expected to be driven by increasing adoption of continuous glucose monitoring systems, offering improved patient outcomes and convenience. Challenges include affordability and ensuring access across all socioeconomic groups, necessitating the engagement of both private and public healthcare initiatives. The market's future hinges on addressing these challenges, fostering innovation in device technology and access, and leveraging the potential of digital health solutions for remote monitoring and patient education. The Russian diabetes care devices market shows strong potential for future growth, fueled by increasing diabetes prevalence and improving healthcare infrastructure. While precise market sizing for Russia is unavailable in the given data, extrapolating from the global market and considering regional factors suggests a considerable market value. The segment of continuous glucose monitoring devices is likely to see the most significant expansion due to its advanced features and improved patient management capabilities. Competition among key international players and the emergence of local players will likely drive innovation and price competitiveness, influencing market access and penetration. Government policies supporting better diabetes care and wider access to affordable technologies will be crucial for sustained growth and ensuring that the benefits of improved treatment reach all segments of the Russian population. Recent developments include: February 2023: Medtronic PLC announced one-year data from the ADAPT study, the first multi-national randomized controlled study comparing the MiniMed 780G advanced hybrid closed loop system (AHCL) performance against multiple daily injections of insulin with an intermittently scanned CGM. The study was done in adults (18 years of age and older) not meeting glycemic targets. At one-year, significant improvements were reproduced in this cross-over group and sustained in those that started on AHCL therapy at the start of the trial., April 2022: CamDiab and Ypsomed announced the partnership to develop and commercialize an integrated automated insulin delivery system to help lessen the burden of diabetes management for people with diabetes in European countries. The new integrated AID system is designed to connect Abbott's FreeStyle Libre 3 sensor, the world's smallest and most accurate continuous glucose monitoring sensor, to CamDiab's CamAPS FX mobile app. It connects with Ypsomed's mylife YpsoPump creating a smart, automated process to deliver insulin based on real-time glucose data.. Notable trends are: Continuous glucose monitoring segment is expected to witness a healthy growth rate over the forecast period.

Comprehensive dataset of 1 Medical equipment manufacturers in Bryansk Oblast, Russia as of July, 2025. Includes verified contact information (email, phone), geocoded addresses, customer ratings, reviews, business categories, and operational details. Perfect for market research, lead generation, competitive analysis, and business intelligence. Download a complimentary sample to evaluate data quality and completeness.

The Russian diabetes care devices market exhibits robust growth potential, projected to reach a market size of $1.34 billion in 2025, expanding at a compound annual growth rate (CAGR) of 4.53% from 2019 to 2033. This growth is fueled by several key factors. The rising prevalence of diabetes in Russia, driven by factors such as increasing urbanization, sedentary lifestyles, and poor dietary habits, is a primary driver. Furthermore, an aging population and improved healthcare infrastructure contribute to heightened demand for advanced diabetes management solutions, including continuous glucose monitors (CGMs), insulin pumps, and blood glucose meters. Government initiatives aimed at improving diabetes care access and affordability also positively impact market expansion. However, economic factors and the potential for price sensitivity among consumers may act as restraints. The market is segmented by device type (CGMs, insulin pumps, blood glucose meters, etc.), end-user (hospitals, clinics, home-use), and distribution channels (pharmacies, online retailers, etc.). Key players such as Roche, Sanofi, Novo Nordisk, and Medtronic are actively competing within this dynamic market, leveraging their technological advancements and strong distribution networks to capture market share. The increasing adoption of telemedicine and remote patient monitoring technologies also presents significant opportunities for growth, particularly in improving patient outcomes and reducing healthcare costs. Future market expansion will likely depend on sustained government support for diabetes care, continued technological innovation, and increased patient awareness regarding effective diabetes management techniques. The forecast period of 2025-2033 promises even greater market expansion, driven by continuous technological improvements. The introduction of new, more accurate, and user-friendly devices, combined with expanding access to affordable healthcare, will likely accelerate market growth. A deeper understanding of regional disparities in diabetes prevalence and access to care will be crucial for targeting specific segments and maximizing market penetration. Companies are investing in research and development to bring innovative devices to the market, further fueling market growth. Strategic partnerships and collaborations within the healthcare ecosystem will play a vital role in streamlining distribution channels and ensuring patient access to advanced diabetes care devices. Key drivers for this market are: Rising Prevalence of Cancer Worldwide, Technological Advancements in Diagnostic Testing; Increasing Demand for Point-of-care Treatment. Potential restraints include: High Cost of Molecular Diagnostic Tests, Lack of Skilled Workforce and Stringent Regulatory Framework. Notable trends are: Continuous glucose monitoring segment is expected to witness a healthy growth rate over the forecast period.

Comprehensive dataset of 1 Medical equipment manufacturers in Altai Krai, Russia as of July, 2025. Includes verified contact information (email, phone), geocoded addresses, customer ratings, reviews, business categories, and operational details. Perfect for market research, lead generation, competitive analysis, and business intelligence. Download a complimentary sample to evaluate data quality and completeness.

Russia Diabetes Drugs And Devices Market size was valued at USD 13.9 Billion in 2024 and is projected to reach USD 32.2 Billion by 2032, growing at a CAGR of 11.1% from 2026 to 2032.

Russia Diabetes Drugs and Devices Market: Definition/ Overview

Diabetes drugs and devices refer to pharmaceutical treatments and medical equipment designed to manage and regulate blood sugar levels in individuals with diabetes. These include insulin therapies, oral medications, continuous glucose monitoring systems, insulin pumps, and glucose test strips. Diabetes drugs, such as metformin and GLP-1 receptor agonists, help control blood sugar levels, while devices like insulin pens, pumps, and CGM systems enhance the precision and convenience of diabetes management. The future scope of diabetes drugs and devices is promising, with ongoing advancements in personalized medicine, artificial pancreas systems, and non-invasive monitoring technologies.

Comprehensive dataset of 18 Medical equipment suppliers in Republic of Dagestan, Russia as of June, 2025. Includes verified contact information (email, phone), geocoded addresses, customer ratings, reviews, business categories, and operational details. Perfect for market research, lead generation, competitive analysis, and business intelligence. Download a complimentary sample to evaluate data quality and completeness.

The Russia Disposables market is anticipated to grow with more than 7.58% CAGR from 2023 to 2028.

Companies in the industry provide repair and maintenance services for measuring, testing and navigating equipment, such as aircraft engine instruments, surveying equipment, radiation detectors and monitoring instruments. Repair services are also provided for irradiation, electromedical and electrotherapeutic equipment such as MRI scanners and pacemakers.

The Russia diabetes drugs and devices market is experiencing robust growth, driven by rising prevalence of diabetes, an aging population, and increasing awareness of disease management. The market, valued at approximately $XX million in 2025 (assuming a reasonable estimate based on global market trends and a CAGR of >4%), is projected to expand significantly over the forecast period (2025-2033). This growth is fueled by several factors, including the increasing adoption of advanced technologies like continuous glucose monitoring (CGM) systems and insulin pumps, improving treatment outcomes and patient convenience. The market is segmented into devices (monitoring and management) and drugs (oral anti-diabetes drugs, insulin, and non-insulin injectables), each contributing to the overall market expansion. While the exact market share of each segment isn't specified, it's reasonable to assume that insulin drugs and CGM devices likely hold significant shares, given global market trends. Government initiatives aimed at improving healthcare access and affordability further contribute to market growth. However, challenges remain, including economic factors that may limit access to expensive therapies for a portion of the population, and potential supply chain disruptions impacting the availability of certain products. The competitive landscape is shaped by both multinational pharmaceutical companies (Novo Nordisk, Sanofi, Eli Lilly) and medical device manufacturers (Medtronic, Abbott), vying for market share through innovation and strategic partnerships. The forecast period (2025-2033) presents substantial opportunities for market players. Focusing on effective disease management strategies, investing in technological advancements, and ensuring affordability and accessibility are crucial for sustained success. Further research and development efforts aimed at innovative therapies and devices, particularly focusing on the unmet needs of the Russian diabetes population, will be key drivers of future growth. Specific regional variations within Russia could also influence market dynamics, requiring targeted marketing and distribution strategies. Analyzing the impact of potential government policies and economic fluctuations will also be crucial for accurate market forecasting. Recent developments include: February 2023: AstraZeneca's Forxiga (dapagliflozin) was approved in the European Union to extend the indication for heart failure with reduced ejection fraction to cover patients across the full spectrum of left ventricular ejection fraction. It includes heart failure with mildly reduced and preserved ejection fraction., February 2023: Medtronic PLC announced one-year data from the ADAPT study, the first multi-national randomized controlled study comparing the MiniMed 780G advanced hybrid closed loop system (AHCL) performance against multiple daily injections of insulin with an intermittently scanned CGM. The study was done in adults (18 years and older) who did not meet glycemic targets. At one year, significant improvements were reproduced in this cross-over group and sustained in those who started AHCL therapy at the start of the trial.. Notable trends are: The continuous Glucose Monitoring Segment is Expected to Witness the Highest Growth Rate Over the Forecast Period.